Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’

Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA

Granules India posts Q4 FY25 PAT at Rs. 152 Cr

The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility

Kerala Ayurveda reports FY25 consolidated revenue higher by 22% at Rs. 137.2 Cr

Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year

Akums reports Q4 FY25 with 12.4% revenue growth

Akums invested Rs. 272 crore in capital expenditure during FY25

Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr

During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore

Zydus Lifesciences’ ‘breast cancer awareness campaign reaches millions

Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness

Sun Pharma Q4 FY25 revenue up 8.5% to Rs. 12,815 Cr

Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items

Lupin to present Phase 1 Data on LNP7457 at ASCO Annual Meeting 2025

Torrent Pharma reports Q4 FY25 PAT at Rs. 498 Cr

The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore

Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr

R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue